<DOC>
	<DOCNO>NCT01260038</DOCNO>
	<brief_summary>This observational study evaluate feasibility implementation personalize treatment strategy base specific tumor marker ( f.i . EGFR-mutation ) routine clinical care set Antwerp region ( Belgium ) .</brief_summary>
	<brief_title>Study NSCLC : Timely Analysis EGFR-mutation Status Feasible Region Antwerp , Belgium .</brief_title>
	<detailed_description>The favourable result number phase III-trials gefitinib NSCLC patient activate EGFR-mutations , result licensing gefitinib indication . This offer prospect true personalize treatment patient NSCLC . Implementation personalize treatment strategy dependent availability adequate tumor sample EGFR-mutation analysis timely report mutation analysis result . Ideally result available patient within 2 week analysis request .</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>age 18 year newly diagnose NSCLC write informed consent tumor sample available mixed histology small cell NSCLC</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Non Small Cell Lung Cancer</keyword>
	<keyword>observational study</keyword>
	<keyword>EGFR mutation analysis</keyword>
	<keyword>EGFR mutation status</keyword>
	<keyword>test turn around time</keyword>
</DOC>